Treeline Biosciences
- Company typePrivate
- Founded2021
- HeadquartersWatertown, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Treeline Biosciences firmographics
Firmographics- Name
- Treeline Biosciences
- Legal name
- Treeline Biosciences, Inc.
- Website
- https://treeline.bio
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Treeline Biosciences industry classification
Industry- Product category
- Precision Oncology Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Treeline Biosciences is headquartered
LocationHeadquarters
- HQ city
- Watertown
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Treeline Biosciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Equity Capital / Venture Financing: Pre-revenue clinical-stage biotech funded almost entirely by private equity. Approximately $1.1B raised cumulatively since 2021, including a $421.78M round in October 2024 and a $200M Series A extension in September 2025; capital is intended to carry multiple programs in parallel rather than milestone-to-milestone.
- Public Market Capital (Pending Reverse Merger): Reverse merger with Standard BioTools (NASDAQ: LAB) announced June 6, 2026, injecting ~$450M net cash into Treeline; combined company to trade on Nasdaq as TRLN with over $900M pro-forma cash funding operations into 2029. No product revenue; capital formation is the revenue model until commercialization.
- Future Out-licensing / Pharma Partnerships (Pipeline): Pipeine supports future co-development, cost- and risk-sharing partnerships with pharma and financial partners per the Mandate page. In-license of SHR2554 from Jiangsu Hengrui (inbound licensing) demonstrates the company already operates licensing structures; commercialization of approved drugs would be the eventual product revenue stream.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
Treeline Biosciences product offering
Product offeringCore offering
Treeline Biosciences is a clinical-stage biopharmaceutical company that designs and develops precision oncology drug candidates using an integrated in-house discovery platform combining wet-lab research with cloud-first computational and machine learning tools. The company currently has three investigational programs in Phase 1 clinical trials: TLN-121 (BCL6 protein degrader for B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor for peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor for KRAS-altered solid tumors). Pre-revenue with no commercial products, Treeline's therapies are accessible only via clinical trial enrollment.
Product overview
Treeline Biosciences operates a single, integrated, target-centric drug discovery platform — the Treeline Discovery Platform — that combines wet-lab R&D at U.S. (Watertown, MA; San Diego, CA) and EU (Basel, Switzerland) facilities with a cloud-first computational platform. The platform is organized around three proven drug-modality toolkits (Oral Small Molecules, Protein Degraders and Glues, and Targeted Therapy Antibody Drug Conjugates/TT-ADCs) and feeds a clinical-stage pipeline of named investigational medicines: TLN-121 (BCL6 degrader, Phase 1, B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor in-licensed from Jiangsu Hengrui, Phase 1, peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor, Phase 1, solid tumors). Treeline's mission is to match compelling disease targets to the best drug approach to deliver category-defining medicines for cancer, autoimmune, and neurological diseases.
Differentiator
Problem solved
Functional benefit
Brands
- TLN-121: Investigational BCL6 protein degrader (Phase 1) for B-cell and T-cell lymphomas.
- TLN-254
- TLN-372
Products and services
- TLN-121 Investigational BCL6-targeted protein degrader in Phase 1 clinical development for B-cell and T-cell lymphomas, designed to selectively remove the BCL6 protein from lymphoma cells while avoiding other targets that could cause toxicity. Listed on ClinicalTrials.gov as NCT07082803.
- TLN-254 Investigational EZH2 inhibitor in Phase 1 clinical development for peripheral T-cell lymphoma and cutaneous T-cell lymphoma. In-licensed from Jiangsu Hengrui Pharmaceuticals (SHR2554) for territories outside China, where the medicine holds conditional approval for relapsed/refractory peripheral T-cell lymphoma. Listed on ClinicalTrials.gov as NCT06733441.
- TLN-372 Investigational pan-KRAS inhibitor in Phase 1 clinical development for solid tumors, designed from first principles to provide deep and constant pan-KRAS target inhibition across KRAS subsets beyond G12C (where FDA-approved medicines exist). Listed on ClinicalTrials.gov as NCT07204340.
Quantifiable outcome
- ~$1.1 billion in capital raised since 2021 founding
- +4 more outcomes
Companies that use Treeline Biosciences
Customer profileSegments5 records
Ideal customer profiles3 records
Treeline Biosciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature7 records
Treeline Biosciences partnerships and signals
Strategic signalScale indicators8 records
Recent moves8 records
Expansion highlights6 records
Treeline Biosciences competitors and assessment
Company assessmentDirect peers
- Revolution Medicines: Clinical-stage precision oncology company developing RAS(ON) inhibitors including a pan-RAS program. Direct comparator to Treeline's pan-KRAS inhibitor TLN-372 and a leading benchmark for KRAS competitive dynamics.
- Arvinas: Pioneer in targeted protein degradation (PROTAC degraders) with clinical-stage oncology assets including BCL6-directed programs. Closest direct competitor to Treeline's BCL6 degrader TLN-121 and to its protein-degrader modality toolkit.
- Kymera Therapeutics: Clinical-stage company developing novel small-molecule protein degraders across oncology and immunology. Directly comparable to Treeline's protein-degrader/glue modality and target-centric discovery approach.
- Foghorn Therapeutics: Clinical-stage precision oncology company focused on chromatin biology and dysregulated gene expression, including EZH2 programs. Directly comparable to Treeline's TLN-254 EZH2 inhibitor in T-cell lymphoma.
- Relay Therapeutics: Clinical-stage precision oncology company using motion-based drug design with deep computational and structural biology capabilities. Comparable target-centric, compute-integrated discovery model with clinical oncology assets.
- Black Diamond Therapeutics: Clinical-stage precision oncology company targeting allosteric mutations on oncogenes, including KRAS. Comparable target-centric discovery model and clinical-stage oncology pipeline with multiple kinase/KRAS programs.
Emerging players
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput wet-lab experimentation with machine learning across multiple therapeutic areas. Comparable compute-first, multi-modality platform approach, though broader in therapeutic scope than Treeline.
- Generate Biomedicines: Generative biology platform company using ML to design novel protein therapeutics. Comparable integration of cloud compute, proprietary data, and ML-driven molecular design, with overlapping modality ambitions in oncology.
- Insitro: ML-driven drug discovery company combining high-throughput biology with proprietary machine learning models. Comparable compute-first, data-flywheel discovery paradigm but focused on metabolic and neurological disease rather than oncology.
- Tango Therapeutics: Clinical-stage precision oncology company using synthetic lethality and DNA damage response approaches. Comparable target-centric clinical-stage oncology biotech with a multi-asset platform model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Treeline Biosciences compliance and trust
Trust signalCompliance3 records
Treeline Biosciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
Treeline Biosciences leadership team
Management profileNumber of profiles
Profiles4 records
Treeline Biosciences subsidiaries and ownership
Company hierarchySubsidiaries1 record
Treeline Biosciences funding detail
Funding detailFunding overview
Funding rounds4 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Treeline Biosciences M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Treeline Biosciences
What does Treeline Biosciences do?
Treeline Biosciences is a clinical-stage biopharmaceutical company that designs and develops precision oncology drug candidates using an integrated in-house discovery platform combining wet-lab research with cloud-first computational and machine learning tools. The company currently has three investigational programs in Phase 1 clinical trials: TLN-121 (BCL6 protein degrader for B-cell and T-cell lymphomas), TLN-254 (EZH2 inhibitor for peripheral and cutaneous T-cell lymphoma), and TLN-372 (pan-KRAS inhibitor for KRAS-altered solid tumors). Pre-revenue with no commercial products, Treeline's therapies are accessible only via clinical trial enrollment.
Is Treeline Biosciences a public or private company?
Treeline Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.
When was Treeline Biosciences founded?
Treeline Biosciences was founded in 2021. It employs 101 to 250 people.
Where is Treeline Biosciences based?
Treeline Biosciences is headquartered in Watertown, United States, in the North America region.
How does Treeline Biosciences make money?
Three revenue lines are on record. Equity Capital / Venture Financing is the primary driver. The others are public Market Capital (Pending Reverse Merger) and future Out-licensing / Pharma Partnerships (Pipeline).
Who are Treeline Biosciences's main competitors?
Direct peers on record are Revolution Medicines, Arvinas, Kymera Therapeutics, Foghorn Therapeutics, Relay Therapeutics and Black Diamond Therapeutics. Emerging players are Recursion Pharmaceuticals, Generate Biomedicines, Insitro and Tango Therapeutics.
Does Treeline Biosciences have an API?
No public API is recorded for Treeline Biosciences.
What industry is Treeline Biosciences in?
Treeline Biosciences's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 8731.